Protein analyzers

Chronicle

2025: Global Protein Analyzers Market Size Reaches $2.74 Billion for the Year

At the end of 2025, the costs in the global market for protein analyzers are estimated at $2.74 billion. More than half of this amount fell on the North American region. The corresponding data is reflected in the Fortune Business Insights study, the results of which were published on December 29, 2025.

Protein analyzers are devices for determining the number and type of proteins in biological fluids (blood, urine), which are critical for diagnosing and monitoring diseases, infections, and autoimmune disorders, assessing nutrition, and overall health. In addition, such devices are widely used in drug development to understand disease mechanisms, assess drug efficacy and safety, search for biomarkers and therapeutic targets, and quality control.

One of the key drivers of the market in question, analysts call the development of pharmaceuticals and biotechnology. Active research and the creation of new therapeutics, including biologics, are driving the demand for protein analyzers to track quality and efficacy. Increasing awareness of the importance of protein markers in diagnosis and personalized medicine is also driving the industry.

Another driver is an increase in the number of patients with chronic diseases such as cancer, cardiovascular ailments and diabetes. In particular, protein analysis is widely used to search for signs of malignancies before symptoms appear, to confirm the diagnosis in conjunction with other methods, to assess the effectiveness of therapy (decrease in markers), to detect relapses, etc. Protein analysis in cardiovascular disease focuses on C-reactive protein (CRP), which is a marker of inflammation in vascular walls, indicating a risk of atherosclerosis and its complications. Protein analysis in diabetes is important for assessing kidney function, controlling inflammation, determining disease type and treatment effectiveness, and for nutritional correction.

Technological advances have a positive impact on the industry. The introduction of automated analyzers and data processing systems improves performance and accuracy, meeting the needs of modern laboratories. The integration of artificial intelligence makes it possible to speed up the analysis of huge amounts of information and reduce the number of errors associated with the human factor. Neural networks are capable of performing laborious routine operations with high efficiency.

The study authors segment the market into analysis kits, reagents/consumables, and instruments. In 2025, almost half of the total revenue was provided by consumables, while sets accounted for 36.4%. Geographically, North America dominates with 51.8%, or $1.42 billion. The contribution of Europe is estimated at $0.71 billion, the Asia-Pacific region - at $0.44 billion. Costs in Latin America were at $0.11 billion. Major industry players on a global scale are:

• Thermo Fisher Scientific;
• Bio-Rad Laboratories;
• Abcam Limited;
• Agilent;
• Merck;
• PerkinElmer;
• Promega;
• Takara Bio.

In 2026, the global protein analyzer market is expected to reach $2.94 billion. At the same time, North America will have $1.63 billion. Fortune Business Insights analysts forecast a CAGR of 7.29% going forward. Thus, by 2034, costs may increase to about $5.15 billion.^[1]

Notes